OasisLMS

Plenary 01: Opening Ceremony and Oral Abstract Presentations

Chairs

Larry J. Copeland (United States of America)
Alexander B. Olawaiye (United States of America)

Welcome, Acknowledgement of Past Chairs and Procession

DURVALUMAB, IN COMBINATION WITH AND FOLLOWING CHEMORADIOTHERAPY, IN LOCALLY ADVANCED CERVICAL CANCER: RESULTS FROM THE PHASE 3 INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CALLA TRIAL

Bradley J. Monk (United States of America)

Distillation & Q&A

Domenica Lorusso (Italy)

UTERINE TRANSPOSITION: FEASIBILITY STUDY

Reitan Ribeiro (Brazil)

Distillation & Q&A

Mario M. Leitao (United States of America)

LATE-BREAKING ABSTRACT PRESENTATION: OVERALL SURVIVAL BY NUMBER OF PRIOR LINES OF CHEMOTHERAPY IN PATIENTS WITH BRCA-MUTATED PLATINUM-SENSITIVE RELAPSED OVARIAN CANCER RECEIVING OLAPARIB TREATMENT OR NON-PLATINUM CHEMOTHERAPY IN SOLO3

Charles A. Leath III (United States of America)

OVERALL SURVIVAL RESULTS FROM ARIEL3: A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA

Robert L Coleman (United States of America)

Distillation & Q&A

Panagiotis A. Konstantinopoulos (United States of America)

SELECTION CRITERIA FOR OMITTING INTERVAL DEBULKING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY FOR ADVANCED HIGH-GRADE SEROUS CARCINOMA OF THE OVARY: KGOG OVSURG-2016/SCORE STUDY

Soo Jin Park (Korea, Republic of)

Distillation & Q&A

Dennis S. Chi (United States of America)

LATE-BREAKING ABSTRACT PRESENTATION: COMPARATIVE EFFECTIVENESS OF HIPEC FOLLOWING INTERVAL CYTOREDUCTIVE SURGERY IN PATIENTS WITH ADVANCED-STAGE OVARIAN CANCER UNDERGOING NEOADJUVANT CHEMOTHERAPY: MULTICENTER, PROSPECTIVE, COHORT STUDY (KGOG 3042)

Yong Jae LEE (Korea, Republic of)

Distillation & Q&A

Leslie M. Randall (United States of America)

PROMISE-2: A ONE STEP DNA-BASED ENDOMETRIAL CANCER MOLECULAR CLASSIFIER

Amy Jamieson (Canada)

Distillation & Q&A

Shannon N. Westin (United States of America)

Awards Ceremony

Plenary 02: Oral Abstract Presentations

Chairs

Ramez N. Eskander (United States of America)
Jessica N. McAlpine (Canada)

RANDOMIZED TRIAL OF PELVIC RADIATION WITH AND WITHOUT CONCURRENT CISPLATIN IN PATIENTS WITH A PELVIC ONLY RECURRENCE OF ENDOMETRIAL CANCER

Ann Klopp (United States of America)

Distillation & Q&A

Carol Aghajanian (United States of America)

POST-HOC ANALYSIS OF OBJECTIVE RESPONSE RATE BY MISMATCH REPAIR PROTEIN DIMER LOSS/MUTATION STATUS IN PATIENTS WITH MISMATCH REPAIR DEFICIENT ENDOMETRIAL CANCER TREATED WITH DOSTARLIMAB

Anna V. Tinker (Canada)

Distillation & Q&A

Eun Ji Nam (Korea, Republic of)

COMBINATION THERAPY WITH TOPOTECAN, PACLITAXEL, AND BEVACIZUMAB IMPROVES PROGRESSION-FREE SURVIVAL IN PATIENTS WITH RECURRENT HIGH-GRADE NEUROENDOCRINE CARCINOMA OF THE CERVIX: A NECTUR STUDY

Michael Frumovitz (United States of America)

NEXT GENERATION SEQUENCING REVEALS A HIGH PREVALENCE OF PATHOGENIC MUTATIONS IN HOMOLOGOUS RECOMBINATION DNA DAMAGE REPAIR GENES AMONG PATIENTS WITH UTERINE SARCOMA.

Dimitrios Nasioudis (United States of America)

Distillation & Q&A

Allan Covens (Canada)

Closing Comments

Featured Speaker, Dr. Tal Zaks

Awards

Speaker Introduction

Robert L Coleman (United States of America)

Developing mRNA medicines: lessons learned from the COVID vaccine

Tal Zaks (United States of America)

Q&A, Discussion and Recognition

Plenary 04: Surviving PARPs – Separating between Opinions and Facts

Chairs

Brian M. Slomovitz (United States of America) Jonathan A. Ledermann (United Kingdom)

SEMINAL ABSTRACT PRESENTATION: ATHENA–MONO (GOG-3020/ENGOT-OV45): A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL EVALUATING RUCAPARIB MONOTHERAPY VS PLACEBO AS MAINTENANCE TREATMENT FOLLOWING RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN OVARIAN CANCER

Bradley J. Monk (United States of America)

SEMINAL ABSTRACT PRESENTATION: FINAL OVERALL SURVIVAL (OS) RESULTS FROM THE PHASE III PAOLA-1/ENGOT-OV25 TRIAL EVALUATING MAINTENANCE OLAPARIB (OLA) PLUS BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER (AOC)

Isabelle L. Ray-Coquard (France)

SEMINAL ABSTRACT PRESENTATION: OVERALL SURVIVAL (OS) AT 7-YEAR (Y) FOLLOW-UP (F/U) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER (OC) AND A BRCA MUTATION (BRCAM) WHO RECEIVED MAINTENANCE OLAPARIB IN THE SOLO1/GOG-3004 TRIAL

Paul A. DiSilvestro (United States of America)

SEMINAL ABSTRACT PRESENTATION: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 ARIEL4 STUDY OF RUCAPARIB VS CHEMOTHERAPY IN PATIENTS WITH ADVANCED, RELAPSED OVARIAN CARCINOMA AND A DELETERIOUS BRCA1/2 MUTATION

Amit Oza (Canada)

SEMINAL ABSTRACT PRESENTATION: PRIMA/ENGOT-OV26/GOG-3012 STUDY: UPDATED LONG-TERM PFS AND SAFETY

Antonio Gonzalez-Martin (Spain)

Panel Discussion

Closing Comments

Plenary 05: Oral Abstract Presentations & Closing Ceremony

Chairs

Christina Fotopoulou (United Kingdom)
Jae-Weon Kim (Korea, Republic of)

IMPACT OF COMORBIDITIES, POSTOPERATIVE COMPLICATIONS AND CENTER VOLUME ON OVERALL SURVIVAL IN A REAL-LIFE COHORT OF 29,879 OVARIAN CANCER PATIENTS

Floriane Jochum (France)

Distillation

Hee Seung Kim (Korea, Republic of)

MIRVETUXIMAB SORAVTANSINE AND BEVACIZUMAB IN FOLATE RECEPTOR ΑLPHA-POSITIVE OVARIAN CANCER: EFFICACY IN PATIENTS WITH AND WITHOUT PRIOR BEVACIZUMAB

David M. O'Malley (United States of America)

ATEZOLIZUMAB AND BEVACIZUMAB IN RECURRENT ENDOMETRIAL CANCER: A PHASE II, MULTI INSTITUTIONAL TRIAL

Katherine Fuh (United States of America)

Distillation

Angelica N. Rodrigues (Brazil)

TRENDS OF METASTATIC LEIOMYOSARCOMA FOLLOWING THE US FOOD AND DRUG ADMINISTRATION (FDA) WARNING ON LAPAROSCOPIC POWER MORCELLATORS

Cortney Eakin (United States of America)

Distillation

Jubilee Brown (United States of America)

PHASE II TRIAL OF PEMBROLIZUMAB AND EPACADOSTAT IN RECURRENT CLEAR CELL CARCINOMA OF THE OVARY: AN NRG ONCOLOGY STUDY

Lilian T. Gien (Canada)

MOLECULAR STRATIFICATION OF OVARIAN CLEAR CELL CARCINOMA PREDICTS CLINICAL OUTCOMES

Sushmita B. Gordhandas (United States of America)

Distillation

Ramez N. Eskander (United States of America)

OUTCOMES OF GYNAECOLOGICAL CANCER SURGERY DURING THE COVID-19 PANDEMIC: RESULTS FROM THE INTERNATIONAL, MULTICENTER, PROSPECTIVE COVIDSURG-GYNAECOLOGICAL CANCER STUDY.

Elaine Leung (United Kingdom)

Distillation

Kevin M. Holcomb (United States of America)

Master Session: Uterine Cancer - Management of Endometrial Cancer in The Molecular Era

In this session we will describe the exciting transformation of the endometrial cancer landscape in the last several years, moving to molecular classification for aid in pathological categorization and providing prognostic and predictive information with which to guide management and clinical trials. Strategies for implementation of molecular classification in both low and high resource settings will be shared, as well as when additional molecular or pathological parameters might add value. Current challenges or as yet unanswered questions in endometrial cancer management will be addressed.

Chairs

Glauco Baiocchi (Brazil)

Ramez N. Eskander (United States of America)

Mansoor R. Mirza (Denmark)

Graziela Zibetti Dal Molin (Brazil)

Jessica N. McAlpine (Canada)

PANEL 1: SURGICAL CONTROVERSIES IN EARLY-STAGE DISEASE

Moderator: Jessica N. McAlpine (Canada)

Should we avoid uterine manipulator in MIS for endometrial cancer?

Mario M. Leitao (United States of America)

Suspicious lymph node during sentinel node biopsy. Is there a role for systematic lymphadenectomy?

Emma C. Rossi (United States of America)

Should all ITC and micrometastasis receive adjuvant treatment?

Andrea Mariani (United States of America)

Can lymph node staging ± other surgical decisions be tailored in context molecular subtype?

Amy Jamieson (Canada)

PANEL 1 - DISCUSSION

PANEL 2: CONTROVERSIES IN ENDOMETRIAL CANCER

Moderator: Graziela Zibetti Dal Molin (Brazil)

How can I get molecular classification/subtyping for patients? Considerations for both low and high resource settings?

Naveena Singh (Canada)

DEBATE: What should be the best approach for endometrioid (grade 3) with small volume long term relapsed disease?

DEBATE: Pro for surgery

Nadeem R. Abu-Rustum (United States of America)

DEBATE: Pro for SBRT

Anuja Jhingran (United States of America)

DEBATE: Pro for systemic treatment

Domenica Lorusso (Italy)

Are we ready to incorporate molecular classification into clinical practice and treatment planning?

Shannon N. Westin (United States of America)

PANEL 2 - DISCUSSION

PANEL 3: NEW TREATMENT OPTIONS FOR ADVANCED AND METASTATIC DISEASE

Moderator: Helen J. MacKay (Canada)

Biomarkers in clinical practice for endometrial cancer: MMR status, TMB, PDL-1, TP53mut, ERpos, HER2+: How can we improve outcomes?

Ana Oaknin (Spain)

What is the concept of platinum-resistance and platinum-free interval in endometrial cancer?

Vicky Makker (United States of America)

PANEL 3 - DISCUSSION

Conclusions and Remarks

Master Session: Vulvar Cancer - Modern Management

This session will focus on controversial issues and difficult to treat scenarios for vulvar cancer. There will be discussion on what’s new, what’s debated, and what’s in the data, as experts bring you the latest updates for squamous cell carcinomas and vulvar melanomas. This will include the new FIGO staging and how it relates to clinical management, new techniques for detecting the sentinel node, controversies in adjuvant radiation, and discussion of vulvar melanoma treatment strategies.

Chairs

David K. Gaffney (United States of America) Lilian T. Gien (Canada) Maaike Oonk (Netherlands)

New FIGO 2021 staging for vulvar cancer – what are the implications for management?

Floor Hinten (Netherlands)

Can we use indocyanine green (ICG) for sentinel nodes in vulvar cancer? Practical tips for the surgeon

Mario M. Leitao (United States of America)

Radiation conundrums: Is there a margin where adjuvant radiation should be considered? ITCs – to treat or not to treat?

Alexandra Taylor (United Kingdom)

Vulvar melanoma: considerations for surgical and adjuvant treatment

Danielle Vicus (Canada)

Q&A

Closing Comments

Master Session: Ovarian Cancer

This session is dedicated to innovations in ovarian cancer biology, surgery and treatment. Speakers in this session will cover the role of “biology” in clinical outcomes and potential for surgical decision making, timing and new approaches. With the growing interest in intraoperative treatments, a critical appraisal of HIPEC will be performed. The second part will discuss current and emerging systemic therapies in the first-line setting and how the ongoing trials may change clinical practice. Next, several “hot topics” in ovarian cancer will be presented, including the mechanisms of resistance to PARP inhibitors, front-line maintenance therapy as part of standard-of-care (SOC) for at least 50% of women with ovarian cancer and the new and very promising developmental therapies. To close this session dedicated to ovarian cancer, a debate on the role of surgery for relapsed disease from the US and European perspectives will be debated.

Chair(s)

Andreas Du Bois (Germany)
Thomas J. Herzog (United States of America) Amit Oza (Canada)
Isabelle L. Ray-Coquard (France)
Anil K. Sood (United States of America)

DEBATE 1: SHARPENING THE SCALPEL WITH MOLECULAR BIOLOGY

Moderator: Andreas Du Bois (Germany)

DEBATE 1: Pro

Anil K. Sood (United States of America)

DEBATE 1: Con

Florian Heitz (Germany)

PANEL 1: POTENTIAL IMPACT ON STANDARD OF CARE: REVIEW OF PENDING TRIALS

Moderator: Amit Oza (Canada)

Potential impact on standard of care: Review of pending trials - Overview

Isabelle L. Ray-Coquard (France)

Potential impact on standard of care: Review of pending trials - Analysis

Bradley J. Monk (United States of America)

PANEL 2: DEVELOPMENTAL THERAPEUTICS (25 min)

Moderator: Isabelle L. Ray-Coquard (France)

Overcoming PARP resistance

Amit Oza (Canada)

Leveraging new pathways for ovarian cancer

Shannon N. Westin (United States of America)

PANEL 3: Current level of evidence supporting HIPEC in clinical care

Moderator: Anil K. Sood (United States of America)

HIPEC: A Critical Appraisal of Promises and Challenges

Kathleen N. Moore (United States of America)

Is it ready for primetime? Addressing the knowledge gaps in HIPEC data

Thomas J. Herzog (United States of America)

DEBATE 2: SECONDARY CYTOREDUCTION

Moderator: Thomas J. Herzog (United States of America)

DEBATE 2: Pro

Andreas Du Bois (Germany)

DEBATE 2: Con

Robert L Coleman (United States of America)

Master Session: Cervical Cancer – Paving the Way to a Treatment Shift in Cervical Cancer

The session will focus on the state of the art of HPV vaccination in cervical cancer prevention programs. Attendees will be informed about the controversies about the surgical treatment in cervical cancer. Resource-based radiotherapy treatment standard will be provided. Latest news in immunotherapy and new agents in the treatment of cervical cancer will be discussed. A deeper focus on molecular and pathologic characteristics of cervical cancer will be discussed.

Chair(s)

Domenica Lorusso (Italy)
Bradley J. Monk (United States of America)
Rene Pareja (Colombia)
Alexandra Taylor (United Kingdom)
Krishnansu Tewari (United States of America)

Why do we still discuss a disease that can be prevented? State of the art of HPV vaccines and precancerous lesion treatment

Agnaldo Lopes (Brazil)

Is cervical cancer a single disease? Pathologic and molecular characterization of a complex tumor

Kay J. Park (United States of America)

Radiotherapy in cervical cancer treatment: resource adapted standard of care

Alexandra Taylor (United Kingdom)

Q&A/Discussion

Bradley J. Monk (United States of America) Pedro T. Ramirez (United States of America)

Hot topics in surgery: Fertility sparing treatments, surgical staging and mini invasive surgery

Christhardt Köhler (Germany)

The role of immunotherapy in cervical cancer

Domenica Lorusso (Italy)

What next: New treatment options in the horizon scanning of cervical cancer

Krishnansu Tewari (United States of America)

Q&A/Discussion

Antibody Drug Conjugates as an Exciting New Drug Class - Industry Symposium by ImmunoGen, Inc.

One of the highest unmet medical needs in gynecologic cancers is platinum resistant ovarian cancer (PROC). Precision medicine in PROC is an exciting opportunity to allow physicians to help patients with cancer care treatment. In this 90-minute session, expert physician leaders will introduce ADCs, focusing on novel therapies and their mechanism of action as well as address associated ADC toxicity and mitigation strategies. Case studies will engage physicians interested in incorporating this treatment into clinical management.

Chair

Robert L Coleman (United States of America)

ADC Technology and Biomarkers Driving Clinical Development

Domenica Lorusso (Italy)

Existing data and expanding into clinical management

Ana Oaknin (Spain)

ADC toxicities and mitigated strategies

Kathleen N. Moore (United States of America)

Case Stories with Audience Response

Robert L Coleman (United States of America)

Changing Paradigms in Endometrial Cancer Treatment - Industry Symposium by Eisai Inc.

This interactive symposium will focus on the changes occurring for the treatment the endometrial cancer patient. It will be cased based on presentations with robust panel discussions and the use of audience polling to guide the discussions.

Chair

Robert W. Naumann (United States of America)

Case presentations

Robert W. Naumann (United States of America)

Panel Case Discussion

Vicky Makker (United States of America)
Jonathan A. Ledermann (United Kingdom)

Domenica Lorusso (Italy)

How do we define non-eligible for Platinum in Ovarian Cancer: Impact of prior therapies and novel strategies for treatment - Industry Symposium by Novocure

The management for patients whom platinum base therapy is no longer an option is challenging. The purpose of this symposium review current treatment options and future strategies for overcoming PARP resistance and helping patients find opportunities beyond platinum therapy.

This expert panel will:

- Defining platinum-based therapy that is no longer an option for patients

- Impact of prior therapies

* MOA and definition on PARP Resistance

* Strategies for overcoming PARP resistance

* Impact of PARP Inhibitors on subsequent therapies

- Outlining new novel strategies

- Defining new, exciting trials in these populations

Chair

David M. O'Malley (United States of America)

Defining platinum base therapy that is no longer an option for patients

Bradley J. Monk (United States of America)

How to define PARP Resistance

Isabelle L. Ray-Coquard (France)

Strategies for overcoming PARP Resistance

Kathleen N. Moore (United States of America)

Defining new novel strategies and exciting trials in these populations

Vanda Salutari (France)

Group Discussion: Impact of PARP Inhibitors on subsequent therapies

Vanda Salutari (France)
Kathleen N. Moore (United States of America) Isabelle L. Ray-Coquard (France)
Bradley J. Monk (United States of America)
David M. O'Malley (United States of America)

It takes a village: Interdisciplinary management of patients with advanced cervical cancer - Industry Symposium by Seagen Inc. & Genmab

•Increased knowledge regarding:

*Clinical data for the FDA Approved and newer therapies in advanced and recurrent/metastatic Cervical Cancer

*The current investigational agents and regimens under evaluation for early, advanced, and recurrent/metastatic Cervical Cancer

•Greater competence related to:

*Selecting therapies and treatments for women with advanced and recurrent/metastatic Cervical Cancer

*Understanding on appropriate Biomarkers

*Understanding antibody drug conjugate technology (ADCs)

*Reducing treatment related issues and proactively managing side effects.

•Greater confidence in their ability to:

*Counsel patients with Cervical cancer on available therapies

*Obtaining the patient perspective

*Discuss options with your pharmacist.

Chair

Leslie M. Randall (United States of America)

Audience Response Initial Case Based Questions

Leslie M. Randall (United States of America)

Recurrent Metistatic Cervical Cancer – What Your Treatment Options Mean to Your Team

Leslie M. Randall (United States of America)

Patient Experience – Case Review 1: Recurrent Cervical Cancer Patient with Stage 4B

Ritu Salani (United States of America)

Patient Experience – Cast 2: Managing Toxicities

Megan Berkenstock (United States of America)

Panel Discussion Regarding Patient Journey and Interdisciplinary Team Interaction

Leslie M. Randall (United States of America)
Ritu Salani (United States of America)
Megan Berkenstock (United States of America)

Sarah Hayward (United States of America)

Shaundra Hall (United States of America)

Learning the ABCs: Advancements in Biomarker-driven Care for Gynecological Malignancies - Industry Symposium by GSK

This GSK-sponsored symposium will explore the progress made in biomarker-driven care for patients with ovarian or endometrial cancer. Our knowledgeable faculty will review how understanding has evolved around molecular targets in these diseases, and how this information guides treatment selection and influences patient outcomes. In turn, the speakers will discuss the current options for biomarker-directed therapy, before giving their perspectives on the key clinical biomarkers that may inform the future standard of care for these gynecological malignancies.

Chair

Susana Campos (United States of America)

Comprehension: our task for today

Susana Campos (United States of America)

What have we learned?

Thomas J. Herzog (United States of America)

Debra L. Richardson (United States of America)

Applying our knowledge

Debra L. Richardson (United States of America) Thomas J. Herzog (United States of America)

Lessons for the future

Susana Campos (United States of America)

Thomas J. Herzog (United States of America)

Debra L. Richardson (United States of America)

Q&A from the audience

Susana Campos (United States of America)

Thomas J. Herzog (United States of America)

Debra L. Richardson (United States of America)

Summary and close

Susana Campos (United States of America)

Molecular Profiling in Gynecologic Cancers: Now and Into the Future - Industry Symposium by Caris Life Sciences

Join Shannon N. Westin, M.D., M.P.H., F.A.C.O.G., Jubilee Brown M.D., and Matthew A. Powell, M.D. as they discuss the importance of molecular profiling for clinical trial inclusion, rare gynecologic tumors, and endometrial cancer.

Chair

Thomas J. Herzog (United States of America)

The Importance of Molecular Profiling in Endometrial Cancer

Matthew Powell (United States of America)

The Future of Molecular Profiling: Clinical Trials Update

Shannon N. Westin (United States of America)

The Utility of Molecular Profiling in Rare Gynecologic Tumors

Jubilee Brown (United States of America)

Platinum-Sensitive Ovarian Cancer - Unmet Medical Need Beyond PARP Inhibitors - Industry Symposium by Mersana Therapeutics, Inc.

There is increasing evidence that PARP inhibition is most effective in the frontline setting which poses the question "what's next?" for patients who progress on PARP inhibitors. Join Dr. Kathleen Moore (USA) as she moderates a discussion amongst Dr. Ramez Eskandar (USA), Dr. Katherine Fuh (USA), Dr. Antonio González Martín (Spain) and the audience to explore the current and future use of PARP inhibitors, response after PARP inhibition, and antibody-drug conjugates as a novel treatment strategy that may fill the unmet medical need for patients with platinum-sensitive disease.

Chair

Kathleen N. Moore (United States of America)

PARP Inhibitors in Frontline Maintenance: The Evolving Treatment Paradigm

Ramez N. Eskander (United States of America)

ARS #1: Frontline Treatment Decisions for HRP Disease

Kathleen N. Moore (United States of America)

Post-PARP Inhibition Data in Platinum-Sensitive Recurrent Disease

Katherine Fuh (United States of America)

ARS #2: What’s Next After PARP Inhibition?

Kathleen N. Moore (United States of America)

Antibody-Drug Conjugates (ADCs) and Ongoing Clinical Trials

Antonio Gonzalez-Martin (Spain)

Q&A and Closing Remarks

Kathleen N. Moore (United States of America)

Secondary Laparoscopic Cytoreduction for Recurrent Ovarian Cancer in Case of Laparoscopic Primary Debulking Surgery

Joong Sub Choi (Republic of Korea)
Jaeman Bae (Republic of Korea)
Won Moo Lee (Republic of Korea)
Un Suk Jung (Republic of Korea)
Jeong Min Eom (Republic of Korea)

Multidisciplinary Approach for Robotic Repair of Rectovaginal Fistula in a Patient with a History of Rectal Cancer

Farr Mezhat (United States of America)
Shadi Seraji (United States of America)
Michael Khalife (United States of America)